Q1 Beat On $3M Milestone, FY26 Guide Reiterated, Improving Long‑Term Visibility

Research evidence excerpt

Q1 Beat On $3M Milestone, FY26 Guide Reiterated, Improving Long‑Term Visibility

Life Science & Diagnostic Tools: Life Science Tools

MaxCyte

TD SECURITIES (USA) LLC EARNINGS UPDATE

May 12, 2026

Price: $0.82 (05/12/2026) Q1 Beat On $3M Milestone, FY26 Guide

Price Target: NA Reiterated, Improving Long-Term Visibility

BUY (1)

ESG SCORE: 70/100

Brendan Smith, Ph.D. THE TD COWEN INSIGHT

646 562 1417

Q1 revs of $9.7M beat the Street’s $7.3M estimate, driven by $3.4M of SPL milestone and

brendan.smith@tdsecurities.com

royalty revenue offsetting core pressure from SPL customer inventory management and

Chad Wiatrowski discontinued programs. FY26 guidance was reiterated at $30–32M, reflecting H1 headwinds

646 562 1361 that should ease into H2. SPL milestone visibility de-risks the near term while late-stage partner

chad.wiatrowski@tdsecurities.com

progress supports a ’27–’28 inflection.

Jacqueline Kisa

646 562 1385 Our Take: De-Risked FY26 With Operating Leverage, SPL Cadence, And Shareholder Returns

jacqueline.kisa@tdsecurities.com In Focus

Key Data MaxCyte’s Q1 performance reinforces our view that FY26 is a transitional year, with SPL

Symbol NASDAQ: MXCT

milestones functioning as intended to offset temporary core revenue headwinds tied to

Beta: 1.37 inventory management and program churn. While core revenue remains pressured in the

52-Week Range: $2.39-$0.68 first half, the reset operating cost base is now clearly visible, with operating expenses down

Market Cap: $87.9MM materially y/y and gross margins remaining resilient, positioning the model for improved

Net Debt (MM): $(85.1) operating leverage as revenue recovers into H2. Management’s confidence in signing three

Cash/Share: $(0.34) SPL agreements this year, in line with the company’s historical annual cadence, further